Literature DB >> 30907492

The tumour microenvironment and immune milieu of cholangiocarcinoma.

Luca Fabris1,2, María J Perugorria3,4,5, Joachim Mertens6, Niklas K Björkström7, Thorsten Cramer8,9,10,11, Ana Lleo12,13, Antonio Solinas14, Hanna Sänger15, Veronika Lukacs-Kornek16, Anja Moncsek6, Alexander Siebenhüner17, Mario Strazzabosco2.   

Abstract

Tumour microenvironment is a complex, multicellular functional compartment that, particularly when assembled as an abundant desmoplastic reaction, may profoundly affect the proliferative and invasive abilities of epithelial cancer cells. Tumour microenvironment comprises not only stromal cells, mainly cancer-associated fibroblasts, but also immune cells of both the innate and adaptive system (tumour-associated macrophages, neutrophils, natural killer cells, and T and B lymphocytes), and endothelial cells. This results in an intricate web of mutual communications regulated by an extensively remodelled extracellular matrix, where the tumour cells are centrally engaged. In this regard, cholangiocarcinoma, in particular the intrahepatic variant, has become the focus of mounting interest in the last years, largely because of the lack of effective therapies despite its rising incidence and high mortality rates worldwide. On the other hand, recent studies in pancreatic cancer, which similarly to cholangiocarcinoma, is highly desmoplastic, have argued against a tumour-promoting function of the tumour microenvironment. In this review, we will discuss recent developments concerning the role of each cellular population and their multifaceted interplay with the malignant biliary epithelial counterpart. We ultimately hope to provide the working knowledge on how their manipulation may lead to a therapeutic gain in cholangiocarcinoma.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cancer associated fibroblasts; extracellular matrix; immune cells; immunotherapy; tumor associated macrophages; tumor reactive stroma

Mesh:

Year:  2019        PMID: 30907492     DOI: 10.1111/liv.14098

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  33 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 2.  Cholangiocarcinoma: novel therapeutic targets.

Authors:  Keisaku Sato; Shannon Glaser; Domenico Alvaro; Fanyin Meng; Heather Francis; Gianfranco Alpini
Journal:  Expert Opin Ther Targets       Date:  2020-02-26       Impact factor: 6.902

Review 3.  Cholangiocarcinoma.

Authors:  Paul J Brindley; Melinda Bachini; Sumera I Ilyas; Shahid A Khan; Alex Loukas; Alphonse E Sirica; Bin Tean Teh; Sopit Wongkham; Gregory J Gores
Journal:  Nat Rev Dis Primers       Date:  2021-09-09       Impact factor: 65.038

Review 4.  Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies.

Authors:  Alla Kuznetsova; Olga Popova; Dmitry Panchenkov; Tatyana Dyuzheva; Alexey Ivanov
Journal:  Clin Exp Med       Date:  2022-09-09       Impact factor: 5.057

Review 5.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

Review 6.  The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma.

Authors:  Oraianthi Fiste; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Michalis Liontos; Konstantinos Koutsoukos; Meletios Athanasios Dimopoulos; Flora Zagouri
Journal:  Vaccines (Basel)       Date:  2021-04-22

Review 7.  The Tumor Microenvironment in Cholangiocarcinoma Progression.

Authors:  Luca Fabris; Keisaku Sato; Gianfranco Alpini; Mario Strazzabosco
Journal:  Hepatology       Date:  2020-11-06       Impact factor: 17.298

Review 8.  Melatonin and circadian rhythms in liver diseases: Functional roles and potential therapies.

Authors:  Keisaku Sato; Fanyin Meng; Heather Francis; Nan Wu; Lixian Chen; Lindsey Kennedy; Tianhao Zhou; Antonio Franchitto; Paolo Onori; Eugenio Gaudio; Shannon Glaser; Gianfranco Alpini
Journal:  J Pineal Res       Date:  2020-03-04       Impact factor: 13.007

9.  USP9X promotes apoptosis in cholangiocarcinoma by modulation expression of KIF1Bβ via deubiquitinating EGLN3.

Authors:  Weiqian Chen; Jingjing Song; Siyu Liu; Bufu Tang; Lin Shen; Jinyu Zhu; Shiji Fang; Fazong Wu; Liyun Zheng; Rongfang Qiu; Chunmiao Chen; Yang Gao; Jianfei Tu; Zhongwei Zhao; Jiansong Ji
Journal:  J Biomed Sci       Date:  2021-06-10       Impact factor: 8.410

Review 10.  New insights on the role of vascular endothelial growth factor in biliary pathophysiology.

Authors:  Valeria Mariotti; Romina Fiorotto; Massimiliano Cadamuro; Luca Fabris; Mario Strazzabosco
Journal:  JHEP Rep       Date:  2021-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.